Celltrion completes clinical trials for Remsima SC for European approval

Published: 2018-09-03 15:53:02

Updated: 2018-09-03 15:53:02

Celltrion completed a Phase III clinical trial to get approval of ‘Remsima SC(CT-P13 SC),’ a subcutaneous injection version of the antibody biosimilar for the treatment of autoimmune therapy ‘Remsima(generic name: infliximab),’ announced that they were about to finish the approval process for Europe.

Celltrion is planning to complete analysis of the clinical trial soon and apply for the Remsim...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.